Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to find the answers to the following questions:
1. What are the highest doses of CBP501 and cisplatin that can be safely administered as
consecutive 2-hours and 1-hour infusions every 21 days?
2. What are the side effects of the combination of CBP501 and cisplatin when given as an
infusion every 21 days?
3. What amount of CBP501 and cisplatin are found in the blood at certain times after it is
given?
4. Are there any substances in your blood or tumor that can tell us about tumor sensitivity
to CBP501 and cisplatin?
5. Will CBP501 given with cisplatin help to treat your cancer?